Skip to main content
. 2017 Sep 7;9(10):837–849. doi: 10.2217/imt-2017-0055

Figure 2. . The potential application of reenergized adoptive cell transfer.

Figure 2. 

Tumor-reactive CD8 T cells will be engineered with a second TCR that recognizes an antigen from a cancer vaccine. Following expansion, these dual-specific CD8 T cells will be infused back into patients and a pathogen-based cancer vaccine will be administered to mediate a vigorous antitumor response.

TCR: T-cell receptor.